Overview

Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder

Status:
Not yet recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.

Phase:

Phase 2

Details

Lead Sponsor:

Biozeus Biopharmaceutical S.A.